Benjamin J. Solomon

Benjamin J. Solomon, MBBS, PhD, FRACP is a Medical Oncologist and Head of Lung Medical Oncology at Peter MacCallum Cancer Centre and Professor at the University of Melbourne. He is one of the most influential thoracic oncologists in the Asia-Pacific region and is recognized internationally for his pivotal role as the global principal investigator of the ALEX trial—the landmark phase III study demonstrating that alectinib is superior to crizotinib as first-line therapy in ALK-positive advanced NSCLC. The ALEX trial established alectinib as a global standard of care for ALK+ NSCLC, demonstrating not only prolonged progression-free survival (34.8 vs 10.9 months) but also dramatic superiority in central nervous system (CNS) activity, with a 12-month CNS progression rate of only 9% with alectinib versus 41% with crizotinib. Dr. Solomon has subsequently led or co-led multiple other pivotal thoracic oncology trials at Peter MacCallum, including studies of lorlatinib, selpercatinib (LIBRETTO-001), and tumor-agnostic NTRK inhibitors. He is a co-investigator in multiple comprehensive genomic profiling initiatives in Australia and has championed routine molecular testing for all advanced NSCLC patients in the Australian context. Dr. Solomon serves on the IASLC Board of Directors and is a member of several international guideline panels.